Related Experiment Video
Updated: Mar 22, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Novel insight into the dangerous connection between diabetes and heart failure
C Lombardi1, V Spigoni2, E Gorga2
1Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Parma and AOU of Parma, Parma, Italy.
Insights
Diabetes mellitus (DM) is a common comorbidity in heart failure (HF), worsening patient outcomes. Diabetic cardiomyopathy involves fibrosis driven by neurohormonal changes, impacting HF progression and type.
Area of Science:
- Cardiology
- Endocrinology
- Pathophysiology
Background:
- Heart failure (HF) affects 1-2% of adults, with diabetes mellitus (DM) as a frequent, prognostically negative comorbidity.
- DM increases the risk of artery disease and post-ischemic HF, and can directly impair myocardial structure and function.
Purpose of the Study:
- To elucidate the pathophysiological mechanisms of diabetic cardiomyopathy.
- To understand the role of fibrosis in disease progression and HF phenotype determination.
Main Methods:
- Review of experimental and clinical investigations into diabetic cardiomyopathy.
- Analysis of neurohormonal alterations contributing to fibrotic processes.
Main Results:
- Fibrosis is identified as a key consequence of converging neurohormonal alterations in diabetic cardiomyopathy.
- These fibrotic changes are fundamental to disease progression and the development of HF with reduced or preserved ejection fraction.
Conclusions:
- Understanding the fibrotic mechanisms in diabetic cardiomyopathy is crucial for managing co-existing HF and DM.
- Future therapies for HF and DM should aim to improve prognosis while maintaining glucose homeostasis and preventing HF development.
Abstract:
Heart failure (HF) affects approximately 1-2 % of the adult population. Diabetes mellitus (DM) is one of the most frequent comorbidities in HF, portending a worse prognosis. DM is associated with an increased risk of artery disease, and consequently of post-ischemic HF, but it may also alter directly the myocardial structure and function. Insights into the pathophysiological mechanisms of diabetic cardiomyopathy have been provided by both experimental and clinical investigations. In recent years, it has emerged that the fibrotic process is a result of the convergence of multiple neurohormonal alterations in diabetic cardiomyopathy at the basis of disease progression and phenotype determination: HF with reduced or preserved ejection fraction. Therapies for HF and DM should demonstrate an improved prognosis and have a neutral effect on glucose homeostasis and the risk of HF development.
More Related Videos
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
08:22Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
Published on: March 20, 2017
Related Concept Videos
Heart Failure I: Introduction
Pathophysiology of Heart Failure
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Heart Failure II: Pathophysiology
Coronary Artery Disease I: Introduction
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...